Connection

Daniel Judge to Adult

This is a "connection" page, showing publications Daniel Judge has written about Adult.
Connection Strength

0.922
  1. Long-Term Efficacy and Safety of ARRY-371797 (PF-07265803) in Patients With Lamin A/C-Related Dilated Cardiomyopathy. Am J Cardiol. 2022 11 15; 183:93-98.
    View in: PubMed
    Score: 0.060
  2. Genetic Dilated Cardiomyopathy Due to TTN Variants Without Known Familial Disease. Circ Genom Precis Med. 2020 12; 13(6):e003082.
    View in: PubMed
    Score: 0.053
  3. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
    View in: PubMed
    Score: 0.052
  4. Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovasc Res. 2017 01; 113(1):102-111.
    View in: PubMed
    Score: 0.041
  5. Absence of a Primary Role for SCN10A Mutations in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. J Cardiovasc Transl Res. 2016 Feb; 9(1):87-9.
    View in: PubMed
    Score: 0.038
  6. Shared desmosome gene findings in early and late onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Transl Res. 2010 Dec; 3(6):663-73.
    View in: PubMed
    Score: 0.026
  7. Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet. 2009 Oct; 2(5):428-35.
    View in: PubMed
    Score: 0.024
  8. Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. Hum Mutat. 2006 Nov; 27(11):1157.
    View in: PubMed
    Score: 0.020
  9. Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2006 Oct 03; 48(7):1416-24.
    View in: PubMed
    Score: 0.020
  10. Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta. 2007 Feb; 1772(2):229-37.
    View in: PubMed
    Score: 0.020
  11. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006 Apr 04; 113(13):1641-9.
    View in: PubMed
    Score: 0.019
  12. The response to cardiac resynchronization therapy in LMNA cardiomyopathy. Eur J Heart Fail. 2022 04; 24(4):685-693.
    View in: PubMed
    Score: 0.015
  13. Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA. 2022 02 01; 327(5):454-463.
    View in: PubMed
    Score: 0.014
  14. Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation. 2021 11 16; 144(20):1600-1611.
    View in: PubMed
    Score: 0.014
  15. Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation. 2021 05 11; 143(19):1852-1862.
    View in: PubMed
    Score: 0.014
  16. Characterization of microsatellite markers flanking FBN1: utility in the diagnostic evaluation for Marfan syndrome. Am J Med Genet. 2001 Feb 15; 99(1):39-47.
    View in: PubMed
    Score: 0.014
  17. Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical Features. Circ Genom Precis Med. 2021 04; 14(2):e003097.
    View in: PubMed
    Score: 0.014
  18. Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Heart Assoc. 2020 02 04; 9(3):e013695.
    View in: PubMed
    Score: 0.013
  19. FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy. J Med Genet. 2020 04; 57(4):254-257.
    View in: PubMed
    Score: 0.013
  20. Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circ Genom Precis Med. 2019 08; 12(8):e002467.
    View in: PubMed
    Score: 0.012
  21. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019 06 14; 40(23):1850-1858.
    View in: PubMed
    Score: 0.012
  22. Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical Surveillance. Circ Genom Precis Med. 2018 07; 11(7):e002237.
    View in: PubMed
    Score: 0.011
  23. Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). J Cardiovasc Electrophysiol. 2018 07; 29(7):1004-1009.
    View in: PubMed
    Score: 0.011
  24. Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circ Arrhythm Electrophysiol. 2018 02; 11(2):e005593.
    View in: PubMed
    Score: 0.011
  25. Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circ Heart Fail. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.011
  26. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017 Sep; 24(3):194-204.
    View in: PubMed
    Score: 0.011
  27. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol. 2017 Jul; 82(1):44-56.
    View in: PubMed
    Score: 0.011
  28. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications. J Am Heart Assoc. 2017 Jun 06; 6(6).
    View in: PubMed
    Score: 0.010
  29. Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Am J Cardiol. 2017 07 01; 120(1):111-117.
    View in: PubMed
    Score: 0.010
  30. Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. JAMA Cardiol. 2017 03 01; 2(3):293-302.
    View in: PubMed
    Score: 0.010
  31. Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation. Heart Rhythm. 2017 06; 14(6):883-891.
    View in: PubMed
    Score: 0.010
  32. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant. 2017 Apr; 36(4):380-385.
    View in: PubMed
    Score: 0.010
  33. Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes. J Card Fail. 2016 07; 22(7):583-5.
    View in: PubMed
    Score: 0.010
  34. Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart. 2016 02 15; 102(4):303-12.
    View in: PubMed
    Score: 0.009
  35. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. Elife. 2015 10 27; 4.
    View in: PubMed
    Score: 0.009
  36. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm. 2016 Jan; 13(1):199-207.
    View in: PubMed
    Score: 0.009
  37. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J. 2016 Mar 01; 37(9):755-63.
    View in: PubMed
    Score: 0.009
  38. Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet. 2015 Jun; 8(3):437-46.
    View in: PubMed
    Score: 0.009
  39. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015 Mar; 8(2):117-27.
    View in: PubMed
    Score: 0.009
  40. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015 Apr 07; 36(14):847-55.
    View in: PubMed
    Score: 0.009
  41. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc. 2014 Dec; 3(6):e001471.
    View in: PubMed
    Score: 0.009
  42. Yield of serial evaluation in at-risk family members of patients with ARVD/C. J Am Coll Cardiol. 2014 Jul 22; 64(3):293-301.
    View in: PubMed
    Score: 0.009
  43. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol. 2014 Oct; 76(4):541-9.
    View in: PubMed
    Score: 0.009
  44. Novel and highly lethal NKX2.5 missense mutation in a family with sudden death and ventricular arrhythmia. Pediatr Cardiol. 2014 Oct; 35(7):1206-12.
    View in: PubMed
    Score: 0.009
  45. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014 Apr; 7(2):230-6.
    View in: PubMed
    Score: 0.008
  46. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. Circulation. 2014 Mar 11; 129(10):1092-103.
    View in: PubMed
    Score: 0.008
  47. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec; 6(6):1011-20.
    View in: PubMed
    Score: 0.008
  48. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2013 Nov; 10(11):1661-8.
    View in: PubMed
    Score: 0.008
  49. Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol. 2013 Dec; 24(12):1311-20.
    View in: PubMed
    Score: 0.008
  50. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013 Oct 01; 62(14):1290-1297.
    View in: PubMed
    Score: 0.008
  51. Malignant arrhythmogenic right ventricular dysplasia/cardiomyopathy with a normal 12-lead electrocardiogram: a rare but underrecognized clinical entity. Heart Rhythm. 2013 Oct; 10(10):1484-91.
    View in: PubMed
    Score: 0.008
  52. Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2013 Nov 05; 62(19):1772-9.
    View in: PubMed
    Score: 0.008
  53. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013 Nov 05; 62(19):1761-9.
    View in: PubMed
    Score: 0.008
  54. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. Circ Arrhythm Electrophysiol. 2013 Jun; 6(3):569-78.
    View in: PubMed
    Score: 0.008
  55. LMNA-associated cardiocutaneous progeria: an inherited autosomal dominant premature aging syndrome with late onset. Am J Med Genet A. 2013 Jul; 161A(7):1599-611.
    View in: PubMed
    Score: 0.008
  56. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 2013 May-Jun; 22(3):189-94.
    View in: PubMed
    Score: 0.008
  57. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012 Nov; 14(11):1199-207.
    View in: PubMed
    Score: 0.007
  58. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2012 Jun 01; 5(3):499-505.
    View in: PubMed
    Score: 0.007
  59. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail. 2012 Apr; 18(4):296-303.
    View in: PubMed
    Score: 0.007
  60. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2012 Jun; 9(6):961-7.
    View in: PubMed
    Score: 0.007
  61. Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2012 Jan 17; 59(3):289-90.
    View in: PubMed
    Score: 0.007
  62. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011 Sep 27; 58(14):1485-96.
    View in: PubMed
    Score: 0.007
  63. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol. 2011 Jun 07; 57(23):2317-27.
    View in: PubMed
    Score: 0.007
  64. Reader- and instrument-dependent variability in the electrocardiographic assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):561-8.
    View in: PubMed
    Score: 0.007
  65. Morphologic variants of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy a genetics-magnetic resonance imaging correlation study. J Am Coll Cardiol. 2009 Apr 14; 53(15):1289-99.
    View in: PubMed
    Score: 0.006
  66. Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2009 Jun; 6(6):769-75.
    View in: PubMed
    Score: 0.006
  67. Familial hypertrophic cardiomyopathy associated with cardiac beta-myosin heavy chain and troponin I mutations. Pediatr Cardiol. 2008 Jul; 29(4):846-50.
    View in: PubMed
    Score: 0.005
  68. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007 Jul 31; 50(5):432-40.
    View in: PubMed
    Score: 0.005
  69. Use of a coronary sinus lead and biventricular ICD to correct a sensing abnormality in a patient with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2006 Mar; 17(3):317-20.
    View in: PubMed
    Score: 0.005
  70. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005 Dec 20; 112(25):3823-32.
    View in: PubMed
    Score: 0.005
  71. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet. 2003 May; 72(5):1154-61.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.